Latitude Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.35M Buy
13,295
+281
+2% +$60.5K 1.33% 14
2026
Q1
$2.83M Buy
13,014
+1,389
+12% +$308K 1.3% 12
2025
Q4
$2.66M Buy
11,625
+241
+2% +$54.9K 1.17% 16
2025
Q3
$2.64M Sell
11,384
-657
-5% -$134K 1.2% 15
2025
Q2
$2.24M Sell
12,041
-22
-0.2% -$4.09K 1.12% 16
2025
Q1
$2.53M Sell
12,063
-291
-2% -$56.6K 1.47% 10
2024
Q4
$2.2M Buy
12,354
+9,783
+381% +$1.8M 1.24% 18
2024
Q3
$508K Sell
2,571
-61
-2% -$11.4K 0.29% 86
2024
Q2
$451K Buy
2,632
+68
+3% +$11.3K 0.28% 79
2024
Q1
$467K Buy
2,564
+25
+1% +$4.31K 0.29% 77
2023
Q4
$393K Sell
2,539
-576
-18% -$84K 0.28% 96
2023
Q3
$464K Sell
3,115
-426
-12% -$62.5K 0.33% 70
2023
Q2
$477K Buy
3,541
+235
+7% +$34.5K 0.33% 69
2023
Q1
$527K Sell
3,306
-44
-1% -$6.73K 0.38% 61
2022
Q4
$541K Buy
3,350
+492
+17% +$75.4K 0.41% 47
2022
Q3
$384K Buy
2,858
+331
+13% +$47.5K 0.32% 78
2022
Q2
$387K Sell
2,527
-5,102
-67% -$780K 0.36% 81
2022
Q1
$1.24M Buy
7,629
+3,297
+76% +$479K 0.28% 79
2021
Q4
$587K Buy
4,332
+1,423
+49% +$168K 0.16% 133
2021
Q3
$314K Buy
+2,909
New +$332K 0.1% 197

Other funds holding ABBV

Latitude Advisors's ABBV Position: Q2 2026 in Review

Latitude Advisors increased its AbbVie (ABBV) stake by 2.2% in Q2 2026, buying an estimated $60.5K and bringing the position to 13,295 shares worth $3.35M. The position accounts for 1.33% of the portfolio, ranked #14.

Latitude Advisors first reported a position in ABBV in Q3 2021 and has held it in 20 quarters since. 1,993 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Latitude Advisors held 13,295 shares of AbbVie worth $3.35M as of Q2 2026.
  • Latitude Advisors bought 281 AbbVie shares in Q2 2026, an estimated $60.5K.
  • AbbVie made up 1.33% of Latitude Advisors's portfolio in Q2 2026, its #14 holding.
  • Latitude Advisors first reported a position in AbbVie in Q3 2021 and has held it in 20 quarters since.
  • 1,993 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Latitude Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.